This research study, called AMAZE 12, is looking into how well the medicine NNC0487-0111 helps people with excess body weight maintain their weight loss. You would receive weekly injections under the skin of either NNC0487-0111 or a placebo (a substance with no active medicine). The study aims to see if NNC0487-0111 is safe and effective. To join, you must be 18 years or older and have a glycated hemoglobin (HbA1c) level less than 6.5%. The main way they will measure success is by looking at the change in body weight between week 40 and week 92. The current recruitment status is unclear, and the study plans to enroll about 600 participants.

Study design

This study is interventional, meaning participants will receive a specific treatment. It involves about 600 participants who will be randomly assigned to receive either NNC0487-0111 or a placebo.

What's involved

You would receive weekly injections under the skin. The primary endpoint for measuring body weight change is between week 40 and week 92.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint for measuring body weight change is between week 40 and week 92, suggesting follow-up during this period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.